Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Consolidated Net Income rose 818.75% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10616.1%. This contributed to the annual value of -$14.0 million for FY2024, which is 8739.19% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Consolidated Net Income is -$4.1 million, which was up 818.75% from -$1.6 million recorded in Q2 2025.
  • Heron Therapeutics' Consolidated Net Income's 5-year high stood at $4.2 million during Q4 2024, with a 5-year trough of -$62.9 million in Q1 2022.
  • Its 5-year average for Consolidated Net Income is -$27.2 million, with a median of -$24.9 million in 2023.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 2074.11% in 2022, then soared by 16573.57% in 2025.
  • Over the past 5 years, Heron Therapeutics' Consolidated Net Income (Quarter) stood at -$53.5 million in 2021, then soared by 61.98% to -$20.4 million in 2022, then soared by 49.79% to -$10.2 million in 2023, then surged by 140.83% to $4.2 million in 2024, then tumbled by 198.08% to -$4.1 million in 2025.
  • Its last three reported values are -$4.1 million in Q3 2025, -$1.6 million for Q2 2025, and $3.2 million during Q1 2025.